INSYQ - INSYQ Plunges Nearly 10% Despite FDA Approving New Drug Application

Insys Therapeutics (OTCPK:INSYQ) experienced a whirlwind in the past months, from witnessing a 48% drop in Q4 revenue and paying a $225 million settlement that sent INSY stock up 12% to jumping 240% after receiving “First Day” motion after its Chapter 11 filing. Today, Insys is back in the news after announcing positive FDA news. And yet, INSYQ stock is tumbling.

Here’s what’s happening.

Based in Phoenix, Arizona, Insys Therapeutics is a pharmaceutical company that uses proprietary technology to create various innovative products. INSYQ has been in the news ...